Skip to content

Ozon Pro: what changed

BE 0806.449.783NACE 32.500, Manufacture of medical and dental instruments and suppliesOther company

Position among the sector peers

What moved between 2024 and 2025

Net result for the year
€10,891
2024 · €24,016-€13,125
Equity
-€8,416
2024 · -€19,307+€10,891
Cash
€747
2024 · €3,173-€2,426
Balance sheet total
€46,249
2024 · €41,055+€5,194

Largest movements

2024 to 2025
Assets
  • Receivables within one year +€8,855

    up €8,855 (+26.8%), from €33,013 to €41,867

    of which Trade receivables: +€8,540

  • Cash -€2,426

    down €2,426 (-76.5%), from €3,173 to €747

    mainly Receivables within one year (-€8,855) and Trade debts (-€7,681)

  • Tangible fixed assets -€1,492

    down €1,492 (-30.7%), from €4,869 to €3,376

    of which Furniture and vehicles: -€1,093

Equity and liabilities
  • Profit (loss) carried forward +€10,891

    up €10,891 (+28.7%), from -€37,907 to -€27,016

  • Trade debts -€7,681

    down €7,681 (-47.7%), from €16,099 to €8,418

  • Tax, wage and social debts +€7,550

    up €7,550 (+183%), from €4,131 to €11,682

    of which Taxes: +€4,950

  • Other debts -€5,567

    down €5,567 (-13.9%), from €40,132 to €34,565

Income statement
  • Financial charges +€7,457

    up €7,457, from -€5,868 to €1,589

  • Taxes +€5,712

    up €5,712 (+722%), from €791 to €6,503

  • Depreciation -€1,963

    down €1,963 (-56.8%), from €3,455 to €1,492

  • Gross operating margin -€1,783

    down €1,783 (-7.7%), from €23,051 to €21,268

Change in the result, 2024 to 2025

effect on the result

For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.

Result 2024 €24,016
Gross operating margin -€1,783
Depreciation +€1,963
Other operating charges -€139
Financial income +€3
Financial charges -€7,457
Taxes -€5,712
Result 2025 €10,891
raises the resultlowers the result

Derived cash bridge

cash 2024 to 2025

The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.

From operations -€2,426
Investment €0
Financing €0
Cash 2024 €3,173
Net result for the year +€10,891
Depreciation +€1,492
Receivables within one year -€8,855
Deferred charges and accrued income -€258
Trade debts -€7,681
Tax, wage and social debts +€7,550
Other debts -€5,567
Cash 2025 €747
brings cash intakes cash out
Every line side by side 35 lines
Line Code 2024 2025 Change %
Total assets 20/58 €41,055 €46,249 +€5,194 +12.7%
Fixed assets 21/28 €4,869 €3,376 -€1,492 -30.7%
Tangible fixed assets 22/27 €4,869 €3,376 -€1,492 -30.7%
Plant, machinery and equipment 23 €905 €506 -€399 -44.1%
Furniture and vehicles 24 €3,964 €2,870 -€1,093 -27.6%
Current assets 29/58 €36,186 €42,872 +€6,686 +18.5%
Amounts receivable within one year 40/41 €33,013 €41,867 +€8,855 +26.8%
Trade receivables 40 €32,973 €41,513 +€8,540 +25.9%
Other amounts receivable 41 €40 €355 +€315 +785%
Cash at bank and in hand 54/58 €3,173 €747 -€2,426 -76.5%
Deferred charges and accrued income 490/1 - €258 +€258
Total equity and liabilities 10/49 €41,055 €46,249 +€5,194 +12.7%
Equity 10/15 -€19,307 -€8,416 +€10,891 +56.4%
Contributions 10/11 €18,600 €18,600 = 0.0%
Profit (loss) carried forward 14 -€37,907 -€27,016 +€10,891 +28.7%
Amounts payable 17/49 €60,362 €54,664 -€5,697 -9.4%
Amounts payable within one year 42/48 €60,362 €54,664 -€5,697 -9.4%
Trade debts 44 €16,099 €8,418 -€7,681 -47.7%
Suppliers 440/4 €16,099 €8,418 -€7,681 -47.7%
Taxes, remuneration and social security 45 €4,131 €11,682 +€7,550 +183%
Taxes 450/3 €4,131 €9,082 +€4,950 +120%
Remuneration and social security 454/9 - €2,600 +€2,600
Other amounts payable 47/48 €40,132 €34,565 -€5,567 -13.9%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets 630 €3,455 €1,492 -€1,963 -56.8%
Other operating charges 640/8 €663 €802 +€139 +20.9%
Gross operating margin 9900 €23,051 €21,268 -€1,783 -7.7%
Operating profit (loss) 9901 €18,933 €18,974 +€41 +0.2%
Financial income 75/76B €6 €9 +€3 +49.8%
Recurring financial income 75 €6 €9 +€3 +49.8%
Financial charges 65/66B -€5,868 €1,589 +€7,457
Recurring financial charges 65 -€5,868 €1,589 +€7,457
Profit (loss) for the period before taxes 9903 €24,807 €17,394 -€7,413 -29.9%
Income taxes 67/77 €791 €6,503 +€5,712 +722%
Profit (loss) for the period 9904 €24,016 €10,891 -€13,125 -54.7%
Profit (loss) for the period to be appropriated 9905 €24,016 €10,891 -€13,125 -54.7%

Value

latest balance sheet 31-12-2025 · indication, not a valuation or advice

Indicative value of the equity

Indication, not a valuation or advice
€39,024 to €56,317

Midpoint €46,230 · 50% capitalised earnings, 50% adjusted equity

Capitalisation rate 12% result over 3 years earnings weight 50%

Adjusted equity -€8,416
Capitalised earnings €86,464 to €121,050
Indication €39,024 to €56,317

Adjusted equity

balance sheet 31-12-2025
Equity (10/15)
-€8,416
Revaluation of assets
€0
Deferred tax on the revaluation
€0
Other adjustment
€0
Adjusted equity
-€8,416

Capitalised earnings

net result for the year (9904)
2025
€10,891
2024
€24,016
2023
€1,410
2022
-€520
2019
€727
Average result
€12,105
Divided by the capitalisation rate
14% / 12% / 10%
Capitalised earnings
€86,464 / €100,875 / €121,050

Limits of the indication

  • Checked holds no market prices or comparable transactions.
  • Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
  • Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
  • The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.

For a valuation to base a decision on, go to a company auditor or a certified accountant.

Calculation and sources

Source: filed annual accounts (NBB) and main activity (KBO). The movements compare the financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. The value is an indication, not a valuation or advice. Prepared on 13 November 2026 via checked.be.